Unicycive Therapeutics Expands ATM Program to $150M, Files $50M S-3 for Equity
UNCY sits 87% above its 52-week low of $3.71 on elevated volume (2.0× avg).
Summary
Unicycive Therapeutics expanded its at-the-market (ATM) equity offering program to a total capacity of $150 million with Guggenheim Securities. Concurrently, the company filed an S-3 shelf registration to offer up to $50 million of common stock under this expanded ATM. This follows an 8-K and S-3 filing on the same day detailing the expansion. The $150 million ATM program represents a significant potential dilution, nearly matching the company's current market capitalization. This substantial capital raise provides liquidity but will likely exert downward pressure on the stock. A critical FDA decision for its OLC drug is expected by June 29th, which will be a key event for the company's future financial needs.
At the time of this announcement, UNCY was trading at $6.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $184.8M. The 52-week trading range was $3.71 to $11.00. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.